AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about its neuroscience ...

AbbVie’s recently acquired Parkinson’s disease candidate tavapadon significantly reduced the burden of disease in a Phase III trial. The Phase III TEMPO-1 trial (NCT04201093) evaluated two ...

AbbVie faces setback as schizophrenia trial for emraclidine fails, but still has potential with other assets from Cerevel.

The most promising of these is Parkinson's disease tavapadon, which in contrast to emraclidine has done well in recent ...

David Risinger’s rating is based on a thorough assessment of AbbVie’s recent clinical trial outcomes and the potential market for its Parkinson’s disease drug, tavapadon, along with an ...

Yet, AbbVie’s emraclidine has floundered where Karuna prospered. AbbVie’s phase 2 trials tested emraclidine as a once-daily, oral monotherapy in adults with schizophrenia experiencing an acute ...

On Monday, AbbVie Inc (NYSE:ABBV) stock plunged after two trials investigating emraclidine as a once-daily, oral monotherapy ...

Tavapadon met the primary endpoint in the pivotal Phase 3, TEMPO-1 fixed-dose monotherapy trial, demonstrating a statistically significant improvement from baseline in the MDS-UPDRS Parts II and III ...

Emraclidine was part of AbbVie's acquisition of Cerevel last year, which also included Tavapadon, which reported positive Phase 3 data. Bristol's Cobenfy is now poised to dominate the ...

The most promising of these is Parkinson's disease tavapadon, which in contrast to emraclidine has done well in recent late-stage trials. Eric Volkman has no position in any of the stocks mentioned.

Tavapadon met the primary endpoint in the pivotal Phase 3, TEMPO-1 fixed-dose monotherapy trial, demonstrating a statistically significant improvement from baseline in the MDS-UPDRS Parts II and ...